<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The aim of the study was to determine the transition rate and factors associated with the progression of normo- and low <z:mp ids='MP_0002959'>microalbuminuria</z:mp> to diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (overt <z:hpo ids='HP_0000093'>proteinuria</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: For 8 years we prospectively observed 1,558 Japanese patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> whose basal urinary albumin:<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (UACR) had been measured as &lt;17.0 mg/mmol at entry </plain></SENT>
<SENT sid="2" pm="."><plain>The incidence of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (UACR &gt;33.9 mg/mmol) was determined by measuring UACR twice a year </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Progression to <z:hpo ids='HP_0000112'>nephropathy</z:hpo> occurred in 74 patients </plain></SENT>
<SENT sid="4" pm="."><plain>The annual transition rate was 0.67%, and was substantially higher for the low-microalbuminuric group than for the normoalbuminuric group (1.85% and 0.23%, respectively; hazard ratio for the low-microalbuminuric group 8.45, p &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>The hazard ratio for an HbA(1c) of 7-9% or ≥9% was 2.72 (p &lt; 0.01) or 5.81 (p &lt; 0.01) relative to HbA(1c) &lt;7.0%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In comparison with individuals with a systolic blood pressure (SBP) of &lt;120 mmHg, the hazard ratios for patients with an SBP of 120-140 mmHg or ≥140 mmHg were 2.31 (p = 0.06) and 3.54 (p &lt; 0.01), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Smoking also affected progression to <z:hpo ids='HP_0000093'>proteinuria</z:hpo> (hazard ratio 1.99, p &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, 30.3% of the low-microalbuminuric group returned to normoalbuminuria (i.e. were in remission) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: These results suggest that if patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> are receiving treatment from diabetologists for <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> when they are in the early stages of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (i.e. normo- or low <z:mp ids='MP_0002959'>microalbuminuria</z:mp>), their rate of transition to <z:hpo ids='HP_0000093'>proteinuria</z:hpo> is considerably lowered, and that differentiating patients with low <z:mp ids='MP_0002959'>microalbuminuria</z:mp> from those with high <z:mp ids='MP_0002959'>microalbuminuria</z:mp> might be clinically useful </plain></SENT>
<SENT sid="10" pm="."><plain>TRIAL REGISTRATION: UMIN Clinical Trials Registry C000000222 </plain></SENT>
</text></document>